COMT Inhibition by Tolcapone Further Improves Levodopa Pharmacokinetics when Combined with a Dual-Release Formulation of Levodopa/Benserazide

Publisher： Karger

E-ISSN： 1421-9913|41|4|206-211

ISSN： 0014-3022

Source： European Neurology, Vol.41, Iss.4, 1999-05, pp. : 206-211

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Single- and Multiple-Dose Pharmacokinetics of Levodopa and 3-O-Methyldopa following a New Dual-Release and a Conventional Slow-Release Formulation of Levodopa and Benserazide in Healthy Volunteers

By  

European Neurology, Vol. 49, Iss. 1, 2002-12 ,pp. : 39-44

Karger

Access to resources Recommend Favorite

Pharmacokinetic Studies with a Dual-Release Formulation of Levodopa, a Novel Principle in the Treatment of Parkinson’s Disease

By  

European Neurology, Vol. 39, Iss. 2, 1998-02 ,pp. : 119-124

Karger

Access to resources Recommend Favorite

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease

By  

Case Reports in Neurology, Vol. 7, Iss. 3, 2015-09 ,pp. : 181-185

Karger

Access to resources Recommend Favorite

The Influence of Levodopa and the COMT Inhibitor on Serum Vitamin B12 and Folate Levels in Parkinson’s Disease Patients

By  

European Neurology, Vol. 58, Iss. 2, 2007-06 ,pp. : 96-99

Karger

Access to resources Recommend Favorite

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?

By  

European Neurology, Vol. 63, Iss. 5, 2010-03 ,pp. : 257-266

Karger

Access to resources Recommend Favorite